The Regulation of Biological Product Marketing: An Introduction
Learn the legal and regulatory requirements surrounding communications about biologics and biosimilars. Define misbranding, label and labeling, and off-label promotion. Identify the basic rules for advertising and promotion.
Nathan A. Beaton, Associate, Latham & Watkins LLP
Kathryn Culver, Associate, Latham & Watkins LLP
This session was recorded as part of FDLI’s Introduction to Biological Products, Including Vaccines, Biosimilars, Cell and Gene Therapies, and Other Advanced Therapies Course in October 2022.
NATHAN A. BEATON is an associate in the Washington, D.C. office of Latham & Watkins and a member of the firm’s Healthcare & Life Sciences Practice. He assists clients with their most complex regulatory, transactional, litigation, and legislative matters involving the Food and Drug Administration (FDA) and other regulatory authorities with jurisdiction over healthcare and biotechnology.
KATHRYN CULVER is an associate in the Washington, D.C. office of Latham & Watkins and a member of the firm’s Healthcare & Life Sciences Practice. She assists clients with their complex regulatory, transactional, investigational, and legislative matters involving the Food and Drug Administration (FDA).Get Access
- +$100 for nonmembers
Internet Explorer and Microsoft Edge are not supported by the checkout process.
Please use Chrome, Firefox, or Safari. If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.
Virtual Learning FAQ
Related Content
